{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T21:31:24Z","timestamp":1652909484995},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s12094-010-0580-y","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T08:10:54Z","timestamp":1288080654000},"page":"701-703","source":"Crossref","is-referenced-by-count":3,"title":["Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab"],"prefix":"10.1007","volume":"12","author":[{"given":"Constanza Maximiano","family":"Alonso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Carlos","family":"S\u00e1nchez Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca Cantos","family":"S\u00e1nchez de Ibarg\u00fcen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam M\u00e9ndez","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel S.","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano Provencio","family":"Pulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,27]]},"reference":[{"key":"580_CR1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/CCO.0b013e32832f3cb7","volume":"5","author":"L.J. Swinnen","year":"2009","unstructured":"Swinnen LJ (2009) Primary central nervous system lymphoma: recent progress, many remaining questions. Curr Opin Oncol 5:393\u2013396","journal-title":"Curr Opin Oncol"},{"key":"580_CR2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1634\/theoncologist.2008-0236","volume":"14","author":"M. Sierra del Rio","year":"2009","unstructured":"Sierra del Rio M, Rousseau A, Soussain C et al (2009) Primary CNS lymphoma in immunocompetent patients. Oncologist 14:526\u2013539","journal-title":"Oncologist"},{"key":"580_CR3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/01.cco.0000142927.88773.7e","volume":"6","author":"K. Hoang-Xuan","year":"2004","unstructured":"Hoang-Xuan K, Camilleri-Bro\u00ebt S, Soussain C (2004) Recent advances in primary CNS lymphoma. Curr Opin Oncol 6:601\u2013606","journal-title":"Curr Opin Oncol"},{"key":"580_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2008-04-149005","volume":"113","author":"M. Montesinos-Rongen","year":"2009","unstructured":"Montesinos-Rongen M, Siebert R, Deckert M (2009) Primary lymphoma of the central nervous system: just DLBCL or not? Blood 113:7\u201310","journal-title":"Blood"},{"key":"580_CR5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1080\/10428190902964776","volume":"50","author":"J.E. Uhm","year":"2009","unstructured":"Uhm JE, Kim KH, Yi SY et al (2009) A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma. Leuk Lymphoma 50:1110\u20131118","journal-title":"Leuk Lymphoma"},{"key":"580_CR6","first-page":"1025","volume":"113","author":"M. Ekenel","year":"2008","unstructured":"Ekenel M, Iwamoto FM, Ben-Porat LS et al (2008) Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. 113:1025\u20131031","journal-title":"Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy"},{"key":"580_CR7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-007-9464-6","volume":"86","author":"A.D. Voloschin","year":"2008","unstructured":"Voloschin AD, Betensky R, Wen PY et al (2008) Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 86:211\u2013215","journal-title":"J Neurooncol"},{"key":"580_CR8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1474-4422(09)70091-2","volume":"8","author":"P.G. Morris","year":"2009","unstructured":"Morris PG, Abrey LE (2009) Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 8:581\u2013592","journal-title":"Lancet Neurol"},{"key":"580_CR9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.nurt.2009.04.013","volume":"3","author":"A.P. Algazi","year":"2009","unstructured":"Algazi AP, Kadoch C, Rubenstein JL (2009) Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics 3:587\u2013597","journal-title":"Neurotherapeutics"},{"key":"580_CR10","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","volume":"26","author":"C. Soussain","year":"2008","unstructured":"Soussain C, Hoang-Xuan K, Taillandier L et al, for the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle Osseuse-Th\u00e9rapie Cellulaire (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle Osseuse-Th\u00e9rapie Cellulaire. J Clin Oncol 26:2512\u20132518","journal-title":"J Clin Oncol"},{"key":"580_CR11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","volume":"101","author":"J.L. Rubenstein","year":"2003","unstructured":"Rubenstein JL, Combs D, Rosenberg J et al (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 101:466\u2013468","journal-title":"Blood"},{"key":"580_CR12","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/foc.2006.21.5.12","volume":"21","author":"K. Jahnke","year":"2006","unstructured":"Jahnke K, Doolittle ND, Muldoon LL, Neuwelt EA (2006) Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus 21:E11","journal-title":"Neurosurg Focus"},{"key":"580_CR13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/07357900600815166","volume":"5","author":"S. Stapleton","year":"2006","unstructured":"Stapleton S, Blaney S (2006) New agents for intrathecal administration. Cancer Invest. 5:528\u2013534.","journal-title":"Cancer Invest"},{"key":"580_CR14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1365-2141.2008.07497.x","volume":"144","author":"J.C. Jaime-P\u00e9rez","year":"2009","unstructured":"Jaime-P\u00e9rez JC, Rodr\u00edguez-Romo LN, Gonz\u00e1lez-Llano O et al (2009) Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol 144:794\u2013795","journal-title":"Br J Haematol"},{"key":"580_CR15","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","volume":"25","author":"J.L. Rubenstein","year":"2007","unstructured":"Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 25:1350\u20131356","journal-title":"J Clin Oncol"},{"key":"580_CR16","first-page":"753","volume":"89","author":"H. Schulz","year":"2004","unstructured":"Schulz H, Pels H, Schmidt-Wolf I et al (2004) Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89:753\u2013754","journal-title":"Haematologica"},{"key":"580_CR17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/IAE.0b013e318192f574","volume":"29","author":"S. Itty","year":"2009","unstructured":"Itty S, Pulido JS (2009) Rituximab for intraocular lymphoma. Retina 29:129\u2013132","journal-title":"Retina"},{"key":"580_CR18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11060-006-9217-y","volume":"81","author":"G. Antonini","year":"2007","unstructured":"Antonini G, Cox MC, Montefusco E et al (2007) Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 81:197\u2013199","journal-title":"J Neurooncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-010-0580-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0580-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:51:22Z","timestamp":1559447482000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-010-0580-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s12094-010-0580-y","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}